Hims & Hers shares tanked after regulators signaled new limits on the production of versions of weight-loss drugs.
Products are independently selected by our editors. We may earn an affiliate commission from links. Do you think Elordi and ...
Key Takeaways Hims & Hers Health shares tumbled Thursday after the Food and Drug Administration (FDA) said Eli Lilly's ...
It was a beautiful day of friendly competition among 4-H youth last weekend as the young ag pupils faced off with their ...
Filming is underway on Netflix's adaptation of Alice Feeney's His & Hers starring Tessa Thompson and Jon Bernthal.
The FDA has resolved Eli Lilly's tirzepatide shortage, but localized supply issues persist. Meanwhile, Hims & Hers Health's ...
Anticipating a 35% CAGR in 2025, Hims & Hers is poised for substantial growth. Read why I maintain my strong buy rating on ...
When you buy through links on our articles, Future and its syndication partners may earn a commission.
Eli Lilly (LLY)'s weight loss drugs Mounjaro and Zepbound are no longer facing supply constraints, as the FDA has removed ...
Hims & Hers stock is currently in the middle of a deep drawdown. Read why I maintain my strong buy rating on HIMS stock.
Stocks were lower Thursday as traders weighed a greater-than-expected increase in weekly jobless claims and awaited the U.S.